儿童非毛细胞型星形细胞瘤的MIB-1标记指数：101例研究

MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.

作者信息

Ho D M, Wong T T, Hsu C Y, Ting L T, Chiang H

机构信息

Department of Pathology and Laboratory Medicine, Veterans General Hospital-Taipei, Taiwan, Republic of China.

出版信息

Cancer. 1998 Jun 15;82(12):2459-66. doi: 10.1002/(sici)1097-0142(19980615)82:12<2459::aid-cncr21>3.0.co;2-n.

DOI:10.1002/(sici)1097-0142(19980615)82:12<2459::aid-cncr21>3.0.co;2-n

PMID:9635540

Abstract

BACKGROUND

The prognosis of pediatric patients with nonpilocytic astrocytoma, and in particular those with anaplastic astrocytoma, is somewhat unpredictable. This study used MIB-1 monoclonal antibody, a proliferative marker that can be used in formalin fixed paraffin embedded tissues, to study nonpilocytic pediatric astrocytoma.

METHODS

Astrocytoma, anaplastic astrocytoma, and glioblastoma specimens excised from a total of 101 pediatric patients during the period from January 1975 to September 1996 were retrieved from the authors' surgical pathology file. Histologic grading of the specimens was performed based on a modified Ringertz system. The proliferative potential of the tumors was estimated by using the MIB-1 labeling index (LI), which was evaluated with morphologic grades of tumors and survival of the patients.

RESULTS

Of the 101 patients, 34 had astrocytoma, 33 had anaplastic astrocytoma, and 34 had glioblastoma. Their mean survival times were 165.2+/-14.9 months (mean+/-standard error; SE), 46.1+/-9.9 months, and 21.8+/-5.6 months, respectively. The mean MIB-1 LI of different tumor grades were as follows: astrocytoma, 3.9+/-4.3 (mean+/-standard deviation; range, 0.0-21.6); anaplastic astrocytoma, 24.3+/-15.6 (range, 1.7-62.8); and glioblastoma, 35.9+/-16.4 (range, 7.36-63.3). The mean survival of the entire group of patients with LIs < or = 11 was 173.2+/-12.2 months (mean+/-SE), and the mean survival of those with LIs > 11 was 20.3+/-4.1 months. The survival of anaplastic astrocytoma patients with LIs < or = 11 was similar to that of astrocytoma patients, whereas the survival of anaplastic astrocytoma patients with LI > 11 was similar to that of patients with glioblastoma.

CONCLUSIONS

The results of the current study show that histopathologic grading can predict the outcome for patients with astrocytomas and glioblastomas, whereas MIB-1 LI can separate better and worse prognostic groups in patients with anaplastic astrocytoma.

摘要

背景

小儿非毛细胞型星形细胞瘤患者，尤其是间变性星形细胞瘤患者的预后在一定程度上难以预测。本研究使用MIB - 1单克隆抗体（一种可用于福尔马林固定石蜡包埋组织的增殖标志物）来研究小儿非毛细胞型星形细胞瘤。

方法

从作者的外科病理档案中检索出1975年1月至1996年9月期间共101例小儿患者切除的星形细胞瘤、间变性星形细胞瘤和胶质母细胞瘤标本。标本的组织学分级基于改良的林格茨系统进行。通过使用MIB - 1标记指数（LI）来估计肿瘤的增殖潜能，该指数与肿瘤的形态学分级和患者的生存率进行评估。

结果

101例患者中，34例为星形细胞瘤，33例为间变性星形细胞瘤，34例为胶质母细胞瘤。他们的平均生存时间分别为165.2±14.9个月（平均值±标准误；SE）、46.1±9.9个月和21.8±5.6个月。不同肿瘤分级的平均MIB - 1 LI如下：星形细胞瘤为3.9±4.3（平均值±标准差；范围，0.0 - 21.6）；间变性星形细胞瘤为24.3±15.6（范围，1.7 - 62.8）；胶质母细胞瘤为35.9±16.4（范围，7.36 - 63.3）。LI≤11的整个患者组的平均生存时间为173.2±12.2个月（平均值±SE），而LI＞11的患者的平均生存时间为20.3±4.1个月。LI≤11的间变性星形细胞瘤患者的生存率与星形细胞瘤患者相似，而LI＞11的间变性星形细胞瘤患者的生存率与胶质母细胞瘤患者相似。